PK/PD of Subcutaneous SCP-111 vs Intravenous Furosemide in Healthy Volunteers

Phase 1, randomised, open-label trial of FuroSCIX ReadyFlow in heart failure (HF) and Fluid overload (2 arms), sponsored by scPharmaceuticals Inc. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration up to 12 hours, Area Under the Curve from Time Zero to Infinity up to 12 hours and 10 more. Started Apr 2024; status: completed.